Most patients report that GLP1 injections cause minimal discomfort
Take the Next Step: If you are interested in learning more about weight loss with semaglutide GLP-1 or Zepbound or would like to discuss a personalized plan, please schedule a consultation with Dr
Tirzepatide is a dual GIP/GLP-1 receptor agonist administered as a weekly subcutaneous injection, producing up to 20.9% weight loss at 72 weeks in Phase 3 trials
GLP-1, or glucagon-like peptide-1, is released by the gut after meals
While both groups had similar rates of adverse events (89% in the liraglutide group and 88% in the placebo group), the liraglutide group reported a higher incidence of gastrointestinal side effects due to dose escalations, however, none resulted in hospitalization
Adults aged 18 years and older with certain body mass indexes (BMI) may be eligible for a GLP-1 agonist medication through a Walgreens Weight Management visit typically a BMI of 30 or above, or a BMI of 27 or above who also have other weight-related health conditions such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS
